Sygnature’s experienced medicinal chemistry and bioscience team have a wealth of expertise and a strong track record of delivery in anti-bacterial, anti-fungal and anti-viral drug discovery. Building on this expertise, Sygnature has established an anti-viral screening platform, to facilitate the support of integrated anti-infective discovery programs.
Established anti-viral assays include:
- Cytopathic effect (CPE) screen: test compounds are evaluated for their ability to inhibit virus-induced CPE. Cells are pre-treated with test compounds and infected with the virus of interest. After a virus-specific incubation period, cells are assessed for their viability relative to an untreated virus-only control.
- Neutralization assays: the virus is incubated with test compounds before suitable cells are infected.
- Plaque-reduction neutralization.
- Microneutralization (measurement of cell survival similar to CPE assays).
- Progeny-reduction assays: Cells are incubated with test compounds and infected with the virus of choice. After a virus-specific incubation time the supernatants are harvested and the virus titre is determined using a method suitable for the selected virus (50% Tissue culture Infective Dose (TCID50), plaque assays, immunoplaques).
- ELISAs: measurement of cytokine secretion in response to viral infection and as a measurement of any inflammatory or anti-inflammatory activity of test compounds.
- RT-qPCR: the detection of viruses in cell supernatant as a diagnostic or as a measure of viral replication.
- Mechanism of action studies: investigation into the effect of viral replication, viral fusion and infectivity as a means of determining the inhibitory mechanism of test compounds.
- Customizable virus production: use of mammalian cell culture for virus growth and harvesting, with titration performed by plaque assay.
- Microscopy-based anti-viral and anti-bacterial high content screening: the measurement of changes in cellular phenotype following viral or anti-viral infections, as well as in response to the use of test compounds.
To complement the range of anti-viral assay available in-house, we also perform host cell cytotoxicity analysis of the compounds to ensure your compound’s efficacy data is meaningful with respect to therapeutic window.